Study Identifies New Therapeutic Strategy for Most Aggressive and Deadly Type of Breast Cancer
Triple negative breast cancer (TNBC) remains the most aggressive and deadly type of breast cancer, but new findings from cancer researchers at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, are pointing the way toward therapeutic strategies that could be tested in clinical trials in the future. Using patient-derived samples in pre-clinical work, researchers discovered that by combining two therapeutic agents they could nudge Triple negative breast cancer cells into a more treatable state. Findings are published in Nature.
"When combined, these therapeutic agents can hijack signals that occur naturally in the body to eliminate breast cells after the cessation of lactation to kill these aggressive cancer cells," said senior author Karen Cichowski, PhD, of the Division of Genetics at Brigham and Women's Hospital (BWH). "Our results provide compelling support for the development of clinical trials to test whether combining these agents could benefit patients with Triple negative breast cancer."
Specifically, the researchers discovered that that by combining two types of agents known as EZH2 and AKT inhibitors, they could coax Triple negative breast cancer cells to differentiate.
Once the cells are differentiated, these agents kill tumor cells by triggering a process similar to involution, which normally occurs when breast tissue returns to a non-lactating state after a mother stops producing breast milk.
The researchers also used machine learning to predict patient responses -- another step that could help set the stage for clinical trials in patients.
Reference: Schade, A.E., Perurena, N., Yang, Y. et al. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature (2024). https://doi.org/10.1038/s41586-024-08031-6
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.